would anyone care to explain why our trials of NNZ 2591 for Prader-Willi syndrome are subject to much stricter safety protocols than our competitors' drugs for the same indication? Is NEU being unfairly treated by the FDA? Why are their safety protocols so lenient?
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-110
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.78 |
Change
1.240(9.89%) |
Mkt cap ! $1.730B | |||
| Open | High | Low | Value | Volume |
| $12.96 | $14.00 | $12.91 | $9.542M | 697.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 404 | $13.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.78 | 1 | 1 |
View Market Depth
| Last trade - 12.41pm 26/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |